Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone

Recruiting now

Conditions studied: Castration-resistant Prostate Cancer

In brief

This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.

Key facts

Study ID

NCT06321679

Run by

European Institute of Oncology

People needed

40

Starts

2020-07-03

Expected to finish

2027-12-31

Last updated by the study team

2024-03-20

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histological diagnosis of castration-resistant prostate cancer,
• Single or multiple bone metastases,
• Life expectancy of over 6 months,
• No current active malignancy other than prostate cancer,
• Provision of written informed consent.

You may not qualify if…

• Absolute contraindication to WB-MRI, CT or BS,
• Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion),
• Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.

Where it is running

• IEO Istituto Europeo di Oncologia — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.